The Novartis Lecture - Greg Verdine
Cancer Chemical Biology
Presented by Greg Verdine, Harvard University
Identification of Broad Spectrum Antiviral Compounds and an Assessment of the Druggability of their Target for Efficacy against RSV
Presented by Simon Bushell, Novartis
Hosted by Dali Sames
Please note special day and times:
MONDAY, April 15, 2013
1:30: Meet the Speaker in 328 Havemeyer
3:30: Tea & Cookies in 328 Havemeyer
4:00: Lecture in 209 Havemeyer
Professor Gregory L. Verdines research interests lie in the emerging
area of chemical biology. He and his
co-workers study biologic processes underlying control of gene expression and
preservation of genomic integrity. He
has made major contributions to the understanding of DNA damage recognition and
repair by base-excision DNA repair enzymes.
He has also pioneered new and powerful approaches for the discovery of
unconventional bioactive ligands for targets that have proven difficult to
target with conventional drugs.
Professor Verdine received his B.S. degree
in 1982 from St. Josephs University and his Ph.D. in 1986 from Columbia
University (under Koji Nakanishi and Maria Tomasz). Following an NIH postdoctoral fellowship with
Chris Walsh at M.I.T. and Harvard Medical School, he joined the Harvard
University Department of Chemistry in 1988.
Verdine was promoted to Full Professor in 1994 and was also named
Harvard College Professor in 2000. In
2002, he was named the Erving Professor of Chemistry, the longest-established
endowed professorship at Harvard.
Verdine has received numerous honors, including the Arthur C. Cope Scholar Award, the Nucleic Acids Award of the Royal Society of Chemistry, the Cruikshank Award of the Gordon Research Conferences, the Nobel Laureate Signature Award of the American Chemical Society (with Anirban Banerjee), and the Fifth Annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research. He has founded numerous drug discovery companies, including Enanta Pharmaceuticals, Gloucester Pharmaceuticals, Eleven Biotherapeutics, and Warp Drive Bio. He is a Venture Partner at Third Rock Ventures, at which he leads the initiative in next-generation therapeutic modalities.
Simon Bushell was born in the UK and received a 1st class B.Sc with honors in Organic chemistry from the University of Manchester in 1997. He continued on, at Manchester, to receive his Ph.D. in 2000, working on the development of new catalytic methods for the asymmetric reduction and allylation of aldehydes and ketones. Simon moved to the US in 2001, and completed a postdoctoral research fellowship at Boston College, Massachusetts, in the laboratory of Ross Kelly, where he helped complete the final synthetic endeavors of that lab to deliver a chemically powered molecular motor. Simon joined Novartis in early 2004, where he has worked within Global Discovery Chemistry with an initial focus on Infectious Diseases. During that time, Simon has worked on, and subsequently led a number of programs, in both the antibacterial and antiviral areas. Most recently, Simons focus has turned to chemogenetics and the interface between medicinal chemistry and pathways biology.
***Rescheduled from December 2012***